Leading provider of healthcare products used for the screening, detection, treatment, monitoring, and tracking of common medical ailments selects the clinivation Global Enterprise Solution for Market Clearance Management as the foundation for managing their global market clearance operations.
Natick, MA, August 15, 2008 – clinivation, Inc. announced today that Natus Medical has selected the the clinivation Global Enterprise Solution for Market Clearance Management enterprise solution for Market Clearance Management.
“Natus Medical is innovative global leader in neurodiagnostic systems and neonatal care, and we are pleased that Natus has selected the the clinivation Global Enterprise Solution for Market Clearance Management Market Clearance Platform as the foundation for managing their global market clearance operations,” said Richard Morroney, R.A.C., C.Q.A., clinivation’s Vice President of Quality and Regulatory Solutions.
About clinivation WorldView® On-Demand Global Regulatory Intelligence
The the clinivation Global Enterprise Solution for Market Clearance Management enterprise solution for Market Clearance Management enables executives and their teams to address the challenges of execution, effective governance, and lean business performance in their global market clearance operations. By enabling excellence in global market clearance operations to advance the revenue intrinsic to market clearance success, the clinivation Global Enterprise Solution for Market Clearance Management liberates revenue that’s trapped-in-process.
About Natus Medical
Headquartered in San Carlo, California, Natus Medical is a leading provider of healthcare products used for the screening, detection, treatment, monitoring, and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. Natus sells its products in the U.S. and over 100 countries worldwide. In 2008 Natus was named by Fortune magazine as one of the nation’s fastest growing small public companies.
For more information, please visit www.natus.com
